Criticism of ‘right to try’ law for experimental drugs after it passes in US image

Chemistry World, June 5, 2018
Anthony King, quoting Jonathan J. Darrow (Student Fellow Alumnus)


Read the Full Article

From the article: 

The US government has controversially announced that it will allow unapproved, experimental drugs to be given to terminally ill patients. The ‘right to try’ law passed by Congress on 22 May will apply to patients who have exhausted all approved treatment options and who cannot take part in a clinical drug trial. The experimental drugs must have passed Phase I safety testing approved by the Food and Drug Administration (FDA).

Critics of the legislation say it is likely to give desperately ill patients false hope and undercut the power of the FDA. Most experimental drugs ultimately fail to help patients. The success rate for cancer drugs entering clinical trials, for example, was recently calculated as 3.6%.


Read the full article!


Photo by emagineart/Flickr

access biotechnology clinical research fda health law policy human subjects research medical safety pharmaceuticals public health regulation